Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026)
Vera Therapeutics (VERA) reported Income from Continuing Operations of 120600000.0 for Q1 2026, down 131.57% on a YoY basis from 382046715.33 in Q1 2025, and down 33.12% quarter-over-quarter from 90593000.0 in Q4 2025.
Vera Therapeutics (VERA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vera Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 120600000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 131.57% year-over-year to 120600000.0; the trailing twelve-month figure through Mar 2026 stood at 367044000.0 (down 771.63% YoY), and the FY2025 full-year result was 1000.0, up 100.0% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 120600000.0, down from 90593000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 91097000.0 in Q4 2024, with the low at 120600000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 27758529.41 across 5 years, with a median of 28832000.0 in 2024.
- The largest YoY upside for Income from Continuing Operations was 334.44% in 2022 against a maximum downside of 263.03% in 2022.
- Vera Therapeutics' Income from Continuing Operations stood at 38915000.0 in 2022, then jumped by 43.21% to 55730000.0 in 2023, then surged by 63.46% to 91097000.0 in 2024, then slumped by 199.45% to 90593000.0 in 2025, then slumped by 33.12% to 120600000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 120600000.0 (Q1 2026), 90593000.0 (Q4 2025), and 80156000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Vera Therapeutics | 2.51 Bn | 1.91 Bn | - | -120.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120.60 Mn |
| Dec 31, 2025 | -90.59 Mn |
| Sep 30, 2025 | -80.16 Mn |
| Jun 30, 2025 | -75.70 Mn |
| Mar 31, 2025 | -52.08 Mn |
| Dec 31, 2024 | 91.10 Mn |
| Sep 30, 2024 | -46.98 Mn |
| Jun 30, 2024 | -34.15 Mn |
| Mar 31, 2024 | -28.83 Mn |
| Dec 31, 2023 | 55.73 Mn |
| Sep 30, 2023 | -20.54 Mn |
| Jun 30, 2023 | -20.65 Mn |
| Mar 31, 2023 | -30.51 Mn |
| Dec 31, 2022 | 38.92 Mn |
| Sep 30, 2022 | -24.82 Mn |
| Jun 30, 2022 | -14.92 Mn |
| Mar 31, 2022 | -17.11 Mn |
| Dec 31, 2021 | -16.60 Mn |
| Sep 30, 2021 | -7.25 Mn |
| Jun 30, 2021 | -5.85 Mn |